How many insider trades does FilingIQ track for ATNM?

FilingIQ tracks 172 Form 4 insider transactions for ATNM (Actinium Pharmaceuticals, Inc.), covering filings from Feb 21, 2014 onwards. 7 of those were filed in the last 90 days.

Are ATNM insiders net buyers or net sellers?

Across the full Form 4 history for ATNM, 26 transactions (15%) were open-market purchases and 120 (70%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ATNM insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ATNM in?

Actinium Pharmaceuticals, Inc. (ATNM) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $32.55M.

ATNM insider trading

NYSE American Healthcare

Actinium Pharmaceuticals, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

172

Last 90 days

Buys / sells

15% / 70%

Market cap

$32.55M

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

Company website: www.actiniumpharma.com

ATNM insider activity at a glance

FilingIQ has scored 172 insider transactions for ATNM since Feb 21, 2014. The most recent filing in our index is dated Sep 2, 2026.

Across the full history, 26 open-market purchases and 120 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ATNM insider trades is 45.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ATNM trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 857

UNITED THERAPEUTICS Corp

BLLN 188

BillionToOne, Inc.

KYMR 169

Kymera Therapeutics, Inc.

THERMO FISHER SCIENTIFIC INC.

Frequently asked

How many insider trades does FilingIQ track for ATNM?: FilingIQ tracks 172 Form 4 insider transactions for ATNM (Actinium Pharmaceuticals, Inc.), covering filings from Feb 21, 2014 onwards. 7 of those were filed in the last 90 days.
Are ATNM insiders net buyers or net sellers?: Across the full Form 4 history for ATNM, 26 transactions (15%) were open-market purchases and 120 (70%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ATNM insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ATNM in?: Actinium Pharmaceuticals, Inc. (ATNM) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $32.55M.

Methodology & sources

Every ATNM insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.